Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Other Non-Current Assets (2023 - 2025)

Historic Other Non-Current Assets for Immunome (IMNM) over the last 3 years, with Q3 2025 value amounting to $4.6 million.

  • Immunome's Other Non-Current Assets rose 445500.0% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 445500.0%. This contributed to the annual value of $4.4 million for FY2024, which is 431100.0% up from last year.
  • According to the latest figures from Q3 2025, Immunome's Other Non-Current Assets is $4.6 million, which was up 445500.0% from $4.4 million recorded in Q2 2025.
  • In the past 5 years, Immunome's Other Non-Current Assets registered a high of $4.6 million during Q3 2025, and its lowest value of $100000.0 during Q1 2023.
  • Moreover, its 3-year median value for Other Non-Current Assets was $100000.0 (2023), whereas its average is $1.7 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first changed by 0.0% in 2024, then soared by 445500.0% in 2025.
  • Quarter analysis of 3 years shows Immunome's Other Non-Current Assets stood at $100000.0 in 2023, then skyrocketed by 4311.0% to $4.4 million in 2024, then increased by 3.26% to $4.6 million in 2025.
  • Its Other Non-Current Assets was $4.6 million in Q3 2025, compared to $4.4 million in Q2 2025 and $4.3 million in Q1 2025.